AGA Nanotech Chosen for Prestigious Innovate UK Microbials Accelerator

AGA Nanotech is proud to announce its selection for the highly competitive Innovate UK Microbials (Microbiome, Biofilms & Phage) Accelerator Programme. This exclusive programme, funded by Innovate UK and co-led by LYVA Labs and Bionow in collaboration with CPI and iiCON, offers extensive support to cutting-edge biotech companies like AGA Nanotech that are developing innovative solutions to combat antimicrobial resistance (AMR).

The Innovate UK Microbials Accelerator Programme is designed to provide biotech companies with a robust framework of support, including access to expert mentorship, technical resources, and tailored training. The programme offers comprehensive market research, competitive analysis, and product development training specifically aimed at advancing ground-breaking technologies like AGA Nanotech’s Battlestar, a novel non-antibiotic antimicrobial solution. The Microbials Accelerator Programme is backed by some of the most prominent players in the biotech sector, including LYVA Labs and Bionow, in partnership with CPI and iiCON, a world-leading infection control consortium. The programme’s mission is to fast-track promising biotech companies by providing a “wrap-around” support package that accelerates product development and market access.

“We are committed to addressing one of the most critical healthcare challenges of our time—AMR. The resources and expertise provided through the Microbials Accelerator Programme will help ensure that Battlestar reaches its full potential in various clinical applications,” said Leah Conway, Principal Scientist at AGA Nanotech.